Physician profile
Michael Shell
NPI 1518925718
$602.51
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $69.47 · 2021: $82.48 · 2022: $53.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $288.91 | 2019-2020 | |
| Boston Scientific Corporation | $106.87 | 2019-2021 | |
| Abbott Laboratories | $100.70 | 2021-2022 | |
| Amgen INC. | $28.16 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.78 | 2019 | |
| Assertio Therapeutics, INC. | $13.45 | 2019 | |
| Lilly USA, LLC | $12.55 | 2020 | |
| Shionogi INC | $10.97 | 2019 | |
| Collegium Pharmaceutical, INC. | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.